TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)

Description

Hypothesis: The investigators hypothesize that changes in the gene region on the short arm of chromosome 9 region 21 (9p21) will alter gene expression in response to ischemia during cardiopulmonary bypass. To test this, the investigators will be taking small pieces of heart tissue from patients undergoing heart surgery before and after this period of ischemia. This will be compared to blood gene expression in blood cells and analyzed with the patients' genetic profile. This might allow us to assess the amount of inflammation that occurs when patients are on the heart-lung machine as well as examine the effects genes have on this critical time period.

Study Start Date

March 2009

Estimated Completion Date

December 2018

Interventions

No interventions cited

Specialties

  • Cardiology: Basic Science/Genetics,Vascular Medicine
  • Internal Medicine: Cardiology
  • Nursing: Cardiology
  • Physician Assistant: Cardiology

MeSH Terms

  • Cardiovascular Diseases

Study ID

Brigham and Women's Hospital -- 2007p002323

Status

Unknown

Trial ID

NCT00985049

Study Type

Observational

Trial Phase

N/A

Enrollment Quota

200

Sponsor

Brigham and Women's Hospital

Inclusion Criteria

  • Aged greater than 20 years
  • Undergoing aortic valve surgery with or without CABG surgery
  • Receive and apical vent as part of the surgery

Exclusion Criteria

  • Will not receive an apical left ventricular vent

Gender

Both

Ages

20 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (2)

Study Location Distance Name Phone Email
Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles None None None
Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.